Establishment Labs | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 53.78 M

Revenue: As of FY2025 Q3, the actual value is USD 53.78 M, beating the estimate of USD 52.28 M.

EPS: As of FY2025 Q3, the actual value is USD -0.38, beating the estimate of USD -0.5259.

EBIT: As of FY2025 Q3, the actual value is USD 2.13 M.

Segment Revenue

• Total Revenue: $146.5 million for the nine months ended September 30, 2025, an increase of $25.0 million, or 20.6%, compared to $121.5 million for the same period in 2024.
• Revenue by Region:
  • EMEA (Europe / Middle East / Africa): $64.5 million for the nine months ended September 30, 2025, compared to $61.1 million for the same period in 2024.
  • Latin America: $28.3 million for the nine months ended September 30, 2025, compared to $27.1 million for the same period in 2024.
  • Asia-Pacific: $25.4 million for the nine months ended September 30, 2025, compared to $32.8 million for the same period in 2024.
  • North America: $28.2 million for the nine months ended September 30, 2025, compared to $0.5 million for the same period in 2024.

Operational Metrics

• Net Loss: $48.4 million for the nine months ended September 30, 2025, compared to $50.1 million for the same period in 2024.
• Gross Margin: 68.8% for the nine months ended September 30, 2025, compared to 65.0% for the same period in 2024.
• Operating Expenses: $135.9 million for the nine months ended September 30, 2025, compared to $110.4 million for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: $50.7 million for the nine months ended September 30, 2025, compared to $37.8 million for the same period in 2024.
• Net Cash Used in Investing Activities: $5.4 million for the nine months ended September 30, 2025, compared to $13.8 million for the same period in 2024.
• Net Cash Provided by Financing Activities: $34.4 million for the nine months ended September 30, 2025, compared to $51.4 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue expanding its market presence in the United States following FDA approval of Motiva Implants in September 2024. The focus will be on increasing sales and market penetration in North America, which has shown significant revenue growth.
• Non-Core Business: The company is exploring opportunities to enhance and broaden its product offerings through potential acquisitions, strategic alliances, and joint ventures. This includes expanding its presence in emerging markets and leveraging its core technology and industry experience.